Genmab Says Ovarian Cancer Drug Met Two Phase 3 Endpoints
Genmab said Rina-S significantly reduced the risk of disease progression in patients with platinum-resistant ovarian cancer.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.